Sign in

Research summary ·

Efficacy and Safety of Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This review and meta-analysis tested inhaled treprostinil in adults with idiopathic pulmonary fibrosis (IPF). IPF is a progressive scarring lung disease. It carries high illness and death rates. Inhaled treprostinil showed lung and vessel signals in pulmonary hypertension linked to interstitial lung disease. It was then tested in IPF trials. The team searched PubMed, Google Scholar and Cochrane CENTRAL. The search covered January 2000 to 2026. They used random-effects meta-analysis. The search found 1552 records. After deduplication, 379 were screened. 85 full-text reports were assessed. The main meta-analysis used TETON-1 and TETON-2. These were the direct IPF randomised trials.

What they found

Inhaled treprostinil improved forced vital capacity (FVC) at 52 weeks. The gain over placebo was 111.28 mL. The range was 77.61 to 144.95. Clinical worsening was reduced. The hazard ratio was 0.69. The range was 0.57 to 0.84. Acute exacerbation was lower. The hazard ratio was 0.52. The range was 0.30 to 0.91. All-cause death did not differ significantly. The hazard ratio was 0.70. The range was 0.47 to 1.05. Stopping for adverse events was more frequent with treprostinil. So were cough and headache.

What it means for patients

The authors say inhaled treprostinil kept lung function stable in the IPF trials. They say it also cut clinical worsening at 52 weeks.

Why it is not certain yet

The main analysis used 2 trials. Treprostinil raised stopping for adverse events, cough and headache. All-cause death did not differ significantly. A review can only be as good as the studies in it.

Source

Efficacy and Safety of Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.

PubMed · PMID 42930051

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Idiopathic pulmonary fibrosis publications